School attendance and juvenile chronic arthritis

Sturge, Claire; Garralda, M. Elena; Boissin, M; Doré, C. J.; Woo, P

doi:10.1093/rheumatology/36.11.1218

Cited by 58 publications

(41 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, more objective measures (such as electronic monitoring) show lower rates of adherence than self-reports. Full treatment adherence to medication in JIA ranges from 68 to 92%, depending on disease subtype, oligoarticular versus polyarticular [11]. Nearly half of JIA patients are non-adherent to NSAID treatment.…”

Section: Discussionmentioning

confidence: 99%

Adherence to methotrexate in juvenile idiopathic arthritis

et al. 2011

View full text Add to dashboard Cite

Non-adherence to treatments for chronic diseases may jeopardize patients' health, increase costs of care, and cause unnecessary clinic appointments and diagnostic studies, as well as additional treatments with potentially serious side effects. Little is known about adherence to methotrexate in pediatric rheumatology. Because this medication is commonly used in JIA, we assessed adherence among children receiving methotrexate in two countries. A total of 76 outpatients (M:F 21:55) with JIA seen in Rio de Janeiro (Brazil) and in Boston (US) taking methotrexate for >2 months were enrolled. Questionnaires were completed by the parents from both centers. Non-adherence was defined as omission of ≥3 prescribed doses in the previous 8 weeks. Patients' ages ranged from 1 to 17 years. Mean time on methotrexate was 20.5 months (±25). Overall rate of non-adherence was 18%. The rate of reported non-adherence was 8% in Boston and 24% in Rio de Janeiro (P = 0.012). The main reason for non-adherence in Boston was "child refused"; in Rio de Janeiro, the main reason was inability to obtain medication. Age had a negative association with adherence (P < 0.0001). Sex, time on methotrexate, route of administration, or concomitant use of other medications were not associated with adherence. Eighteen percent of children with JIA prescribed methotrexate were non-compliant. The difference in reasons for poor adherence between patients in Rio de Janeiro and Boston suggests that different strategies may be needed to improve adherence in these 2 settings. The rate of non-adherence warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to methotrexate in juvenile idiopathic arthritis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Young people and their families may prioritise education over treatment during the key educational stages in later adolescence; for example, missed appointments, refusal to do lunchtime treatments, or refusal of regular transfusions in sickle cell disease due to missed school. 32 The way that health professionals deal with the educational system is key in reducing the impact of intensive educational requirements on chronic illness management. 31 33 Teenagers with chronic conditions are more likely than their healthy peers to miss school due to their condition or to the treatment they need.…”

Section: Socialmentioning

confidence: 99%

The adolescent with a chronic condition. Part I: developmental issues

Michaud

Viner

2004

Archives of Disease in Childhood

403

336

View full text Add to dashboard Cite

“…However, attendance is poorer in polyarticular disease, 17 and high rates of psychological deviance (i.e. departure from expected values) were reported.…”

Section: Prognosismentioning

confidence: 98%

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept

Cummins

Connock

Fry‐Smith

et al. 2002

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Competing interests: Dr Carole Cummins is an investigator on a research proposal approved by the British Paediatric Rheumatology Group for a biologics and new drug paediatric rheumatology register, which will include patients taking etanercept. Funding is to be sought from Wyeth Laboratories. None of the other authors have any competing interests. HTAWyeth Laboratories submitted some information to the National Institute for Clinical Excellence in confidence and references to this information have been removed from this HTA report. However, it should be noted that the Institute's Appraisal Committee had access to the full report when drawing up their guidance on the use of etanercept for children with juvenile idiopathic arthritis. Published August 2002This report should be referenced as follows:Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. 2002;6(17). Health Technol AssessHealth Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see opposite). NHS R&D HTA ProgrammeT he NHS R...

show abstract

School attendance and juvenile chronic arthritis

Cited by 58 publications

References 14 publications

Adherence to methotrexate in juvenile idiopathic arthritis

Adherence to methotrexate in juvenile idiopathic arthritis

The adolescent with a chronic condition. Part I: developmental issues

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept

Contact Info

Product

Resources

About